International Journal of Hematology

, Volume 99, Issue 2, pp 141–153

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up

  • Shin Fujisawa
  • Hirohisa Nakamae
  • Michinori Ogura
  • Ken-ichi Ishizawa
  • Masafumi Taniwaki
  • Atae Utsunomiya
  • Kosei Matsue
  • Yasushi Takamatsu
  • Kensuke Usuki
  • Mitsune Tanimoto
  • Yoji Ishida
  • Hideki Akiyama
  • Shintaro Onishi
Original Article

DOI: 10.1007/s12185-013-1470-1

Cite this article as:
Fujisawa, S., Nakamae, H., Ogura, M. et al. Int J Hematol (2014) 99: 141. doi:10.1007/s12185-013-1470-1

Abstract

Dasatinib is a highly potent BCR-ABL kinase inhibitor with established efficacy and safety in imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. In the global phase III DASISION trial in patients with newly diagnosed chronic phase CML (CML-CP), dasatinib was found to have an acceptable safety profile and demonstrated significantly faster and higher rates of complete cytogenetic response (CCyR) and major molecular response (MMR) compared with imatinib. Here, we report the results of a subset analysis of Japanese patients enrolled in the DASISION trial, showing safety and efficacy profiles generally consistent with patients enrolled worldwide, including higher response rates (CCyR, MMR) with dasatinib compared with imatinib and similar high rates of progression-free and overall survival with both therapies. However, the small sample size of the present study limits the strength of these conclusions, and further exploration is needed to confirm any differences observed in Japanese patients compared with the total treated population. These findings support the use of dasatinib 100 mg QD as a first-line treatment in Japanese patients with newly diagnosed CML-CP.

Keywords

Dasatinib Japanese CML-CP First-line Newly diagnosed 

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Shin Fujisawa
    • 1
  • Hirohisa Nakamae
    • 2
  • Michinori Ogura
    • 3
  • Ken-ichi Ishizawa
    • 4
  • Masafumi Taniwaki
    • 5
  • Atae Utsunomiya
    • 6
  • Kosei Matsue
    • 7
  • Yasushi Takamatsu
    • 8
  • Kensuke Usuki
    • 9
  • Mitsune Tanimoto
    • 10
  • Yoji Ishida
    • 11
  • Hideki Akiyama
    • 12
  • Shintaro Onishi
    • 13
  1. 1.Department of HematologyYokohama City University Medical CenterYokohamaJapan
  2. 2.Department of Hematology and Stem Cell TransplantationOsaka City University HospitalOsakaJapan
  3. 3.Department of Hematology and OncologyNagoya Daini Red Cross HospitalAichiJapan
  4. 4.Division of HematopathologyTohoku University HospitalSendaiJapan
  5. 5.Department of HematologyUniversity Hospital, Kyoto Prefectural University of MedicineKyotoJapan
  6. 6.Department of HematologyImamura Bun-in HospitalKagoshimaJapan
  7. 7.Department of HematologyOncology, Kameda Clinic of Medical Corporation TesshokaiKamogawaJapan
  8. 8.Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal MedicineFukuoka University HospitalFukuokaJapan
  9. 9.Division of HematologyKanto Medical Center NTT ECTokyoJapan
  10. 10.Department of Hematology and OncologyOkayama University HospitalOkayamaJapan
  11. 11.Department of Hematology and Oncology, Internal MedicineIwate Medical University School of MedicineMoriokaJapan
  12. 12.Hematology DivisionTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  13. 13.Bristol-Myers K.K. and Otsuka Pharmaceutical Co., Ltd.TokyoJapan

Personalised recommendations